Fundraising Fox
Enveric Biosciences
NASDAQ: ENVBCambridge, US · Delaware corporation
Find your way into Enveric Biosciences
Sign up to see every warm intro you have to Enveric Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Enveric Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Enveric Biosciences is a biotechnology company developing neuroplastogenic small-molecule drugs for neuropsychiatric and mental health disorders. It uses a proprietary discovery platform called The Psybrary to build an intellectual property portfolio of novel molecules targeting specific mental health indications.
Founders & leadership
KM
Kevin M. CoveneyChief Financial OfficerKevin M. Coveney is Chief Financial Officer of Enveric Biosciences, a biotechnology company developing neuroplastogenic small-molecule drugs for mental health disorders. He brings over 20 years of experience in biotechnology and life sciences finance, operations, and SEC reporting, with a track record leading finance and accounting functions at biotech start-ups through multiple equity funding rounds.
SD
Srinidhi DevanurExecutive Vice Chairman
VP
Viraj PatelChief Financial Officer
BK
Brent KeltonChief Executive Officer
JT
Joseph TuckerChief Executive Officer and DirectorDr. Joseph Tucker holds a PhD in Biochemistry and Molecular Biology from the University of Calgary and has spent over 25 years in biotechnology leadership, including CEO or executive roles at multiple companies that achieved public listing or acquisition; his background includes clinical development across neurological and respiratory indications, regulatory interactions with major health authorities, and licensing partnerships with large biopharmaceutical firms.
JT
Joseph Tucker, Ph.D.Chief Executive Officer, Director
DA
Dimitrios AngelisNamed on SEC filing
JS
James ShadNamed on SEC filing
DL
David LuciNamed on SEC filing
RS
Robert ShawahNamed on SEC filing
Board
MS
Marcus SchabackerBoard director
SD
Reported raises · per SEC filings
Form D private placements$25.9M disclosed across 5 of 8 rounds · 2018–2026
▶$5MraisedMay 2026 · 4 investors · BiotechnologyRule 506(b)
▶$5MraisedMay 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin M. CoveneyExecutive Officer
- Michael SchabackerDirector
- George W. KeglerDirector
- Sheila DeWittDirector
- Joseph E. TuckerExecutive Officer, Director
- Frank PasqualoneDirector
- Michael D. WebbDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Sales commissions
- $350K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedFeb 2026 · 5 investors · BiotechnologyRule 506(b)
▶$1.5MraisedFeb 2026 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael D. WebbDirector
- Sheila DeWittDirector
- Joseph E. TuckerExecutive Officer, Director
- Kevin M. CoveneyExecutive Officer
- Frank PasqualoneDirector
- Marcus SchabackerDirector
- George W. KeglerDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Sales commissions
- $101.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$106.6KraisedDec 2025 · 15 investors · BiotechnologyRule 506(b)
▶$106.6KraisedDec 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sheila DeWittDirector
- George W. KeglerDirector
- Kevin M. CoveneyExecutive Officer
- Marcus SchabackerDirector
- Frank PasqualoneDirector
- Michael D. WebbDirector
- Joseph E. TuckerExecutive Officer, Director
- Offering amount
- $106.6K
- Amount sold
- $106.6K
- Sales commissions
- $217.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedOct 2025 · 12 investors · PharmaceuticalsRule 506(b)
▶Undisclosed amountofferedOct 2025 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marcus SchabackerDirector
- Kevin M. CoveneyExecutive Officer
- Sheila DeWittDirector
- Joseph E. TuckerExecutive Officer, Director
- Frank PasqualoneDirector
- Michael D. WebbDirector
- George W. KeglerDirector
- Sales commissions
- $155.3K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.8MraisedApr 2023 · 2 investors · PharmaceuticalsRule 506(b)
▶$12.8MraisedApr 2023 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph TuckerExecutive Officer, Director
- Bob DagherExecutive Officer
- Marcus SchabackerDirector
- Douglas LindDirector
- Frank PasqualoneDirector
- Peter FacchiniExecutive Officer
- George KeglerDirector
- Michael D. WebbDirector
- Bevin O'NeilDirector
- Kevin CoveneyExecutive Officer
- Avani KanubaddiExecutive Officer
- Offering amount
- $12.8M
- Amount sold
- $12.8M
- Sales commissions
- $560K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.4MofferedFeb 2021 · 6 investors · PharmaceuticalsRule 506(b)
▶$8.4MofferedFeb 2021 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David JohnsonExecutive Officer, Director
- Avani KanubaddiExecutive Officer, Director
- Sol MayerDirector
- Marcus SchabackerDirector
- John Van BuitenExecutive Officer
- George KeglerDirector
- Offering amount
- $8.4M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.2MofferedJan 2021 · 6 investors · PharmaceuticalsRule 506(b)
▶$8.2MofferedJan 2021 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marcus SchabackerDirector
- Sol MayerDirector
- George KeglerDirector
- Avani KanubaddiExecutive Officer
- John Van BuitenExecutive Officer
- David JohnsonExecutive Officer, Director
- Offering amount
- $8.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedAug 2018 · 4 investors · Business ServicesRule 506(b)
▶$6.6MraisedAug 2018 · 4 investors · Business Services
Rule 506(b)Officers, directors & promoters on the filing
- Dimitrios AngelisDirector
- Srinidhi DevanurExecutive Officer, Director
- James ShadDirector
- Viraj PatelExecutive Officer
- David LuciDirector
- Robert ShawahDirector
- Brent KeltonExecutive Officer
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- Sales commissions
- $456.9K
- Placement agents
- A.G.P. / Alliance Global Partners
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanksFinancial analysis and stock research platform.
Companies working in the same space as Enveric Biosciences.
In the news
Enveric Biosciences (NASDAQ: ENVB) deepens Q2 loss while pushing EB-003 toward trialsstocktitan.net · Aug 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 - AOLaol.com · Aug 2026Frequently asked questions
- What does Enveric Biosciences do?
- Enveric Biosciences is a biotechnology company developing neuroplastogenic small-molecule drugs for neuropsychiatric and mental health disorders. It uses a proprietary discovery platform called The Psybrary to build an intellectual property portfolio of novel molecules targeting specific mental health indications.
- How much funding has Enveric Biosciences raised?
- Enveric Biosciences has disclosed $25.9M raised across 5 of its 8 known rounds.
- Where is Enveric Biosciences headquartered?
- Enveric Biosciences is headquartered in Cambridge, US.